List of Excipients in API TEPOTINIB HYDROCHLORIDE
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing TEPOTINIB HYDROCHLORIDE
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| EMD Serono Inc | TEPMETKO | tepotinib hydrochloride | 44087-5000 | CELLULOSE, MICROCRYSTALLINE | 2030-03-19 |
| EMD Serono Inc | TEPMETKO | tepotinib hydrochloride | 44087-5000 | CROSPOVIDONE | 2030-03-19 |
| EMD Serono Inc | TEPMETKO | tepotinib hydrochloride | 44087-5000 | FERRIC OXIDE RED | 2030-03-19 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for TEPOTINIB HYDROCHLORIDE
Excipient focus: CELLULOSE, MICROCRYSTALLINE
TEPOTINIB HYDROCHLORIDE drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| EMD Serono Inc | tepotinib hydrochloride | 44087-5000 |
| >Company | >Ingredient | >NDC |
TEPOTINIB HYDROCHLORIDE drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
TEPOTINIB HYDROCHLORIDE drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| EMD Serono Inc | tepotinib hydrochloride | 44087-5000 |
| >Company | >Ingredient | >NDC |
TEPOTINIB HYDROCHLORIDE drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
TEPOTINIB HYDROCHLORIDE drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| EMD Serono Inc | tepotinib hydrochloride | 44087-5000 |
| >Company | >Ingredient | >NDC |
TEPOTINIB HYDROCHLORIDE drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
TEPOTINIB HYDROCHLORIDE drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| EMD Serono Inc | tepotinib hydrochloride | 44087-5000 |
| >Company | >Ingredient | >NDC |
TEPOTINIB HYDROCHLORIDE drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
TEPOTINIB HYDROCHLORIDE drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| EMD Serono Inc | tepotinib hydrochloride | 44087-5000 |
| >Company | >Ingredient | >NDC |
TEPOTINIB HYDROCHLORIDE drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
TEPOTINIB HYDROCHLORIDE drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| EMD Serono Inc | tepotinib hydrochloride | 44087-5000 |
| >Company | >Ingredient | >NDC |
TEPOTINIB HYDROCHLORIDE drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
TEPOTINIB HYDROCHLORIDE drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| EMD Serono Inc | tepotinib hydrochloride | 44087-5000 |
| >Company | >Ingredient | >NDC |
TEPOTINIB HYDROCHLORIDE drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
TEPOTINIB HYDROCHLORIDE drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| EMD Serono Inc | tepotinib hydrochloride | 44087-5000 |
| >Company | >Ingredient | >NDC |
TEPOTINIB HYDROCHLORIDE drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
TEPOTINIB HYDROCHLORIDE drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| EMD Serono Inc | tepotinib hydrochloride | 44087-5000 |
| >Company | >Ingredient | >NDC |
TEPOTINIB HYDROCHLORIDE drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
TEPOTINIB HYDROCHLORIDE drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| EMD Serono Inc | tepotinib hydrochloride | 44087-5000 |
| >Company | >Ingredient | >NDC |
TEPOTINIB HYDROCHLORIDE drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRIACETIN
TEPOTINIB HYDROCHLORIDE drug variants containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| EMD Serono Inc | tepotinib hydrochloride | 44087-5000 |
| >Company | >Ingredient | >NDC |
TEPOTINIB HYDROCHLORIDE drug variants not containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch